Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Behav Brain Res ; 357-358: 82-87, 2019 01 14.
Article in English | MEDLINE | ID: mdl-29113874

ABSTRACT

The effects of the 5-HT1A receptor blocker pindolol and the 5-HT releasing and uptake blocking agent d-fenfluramine, both used as indirect serotonin agonists, on flumazenil-induced acute anxiety reactions were studied in panic disorder patients to test the hypothesis that serotonin (5-HT) inhibits neural systems mediating panic attacks. Thirty never treated or drug free PD patients (16 females) aged 22-49 y (mean ±â€¯SD, 32.9 ±â€¯8) received single doses of d-fenfluramine (n = 10; 30 mg, p.o.), pindolol (n = 10; 5 mg, p.o.), or placebo (n = 10) 90 and 45 min before a challenge test with flumazenil (1.5 mg, i.v., in 10 min), under double-blind conditions. Panic attacks occurred in 5 control subjects (placebo-flumazenil group), 5 subjects in the pindolol group and in 7 in the d-fenluramine pre-treated patients. Patients experiencing anxiety attacks following flumazenil reported higher increases in anxiety scores. Respiratory rate increases were not different between patients experiencing or not a panic attack. Despite sample size limitation, this study suggests that flumazenil induced anxiety reaction is not a good pharmacological model of panic attacks, considering the absence of serotonergic modulation of its effects.


Subject(s)
Anxiety/drug therapy , Fenfluramine/therapeutic use , Pindolol/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Serotonin Antagonists/therapeutic use , Adult , Anxiety/chemically induced , Anxiety/etiology , Female , Flumazenil/adverse effects , GABA Modulators/adverse effects , Humans , Male , Middle Aged , Panic Disorder/complications , Psychiatric Status Rating Scales , Regression Analysis , Young Adult
2.
Acta Psychiatr Scand ; 121(3): 216-26, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19694635

ABSTRACT

OBJECTIVE: To assess the rate of comorbidities and the functional impairment associated with the social anxiety disorder (SAD), with an emphasis on the so-called subthreshold clinical signs and symptoms. METHOD: Psychiatric comorbidities and psychosocial functioning were evaluated in 355 volunteers (college students) who had been diagnosed as SAD (n = 141), Subthreshold SAD (n = 92) or Controls (n = 122). RESULTS: The rate of comorbidities was 71.6% in the SAD group and 50% in subjects with Subthreshold SAD, both significantly greater than Controls (28.7%). Concerning psychosocial functioning, the SAD group had higher impairment than the other two groups in all domains evaluated, and subjects with Subthreshold SAD presented intermediate values. CONCLUSION: The rates of psychiatric comorbidities and the impairment of psychosocial functioning increase progressively along the spectrum of social anxiety. The fact that Subthreshold SAD causes considerable disability and suffering in comparison with control subjects justifies a review of the validity of the diagnostic criteria.


Subject(s)
Phobic Disorders/diagnosis , Adolescent , Adult , Anxiety/diagnosis , Anxiety/psychology , Comorbidity , Diagnosis, Differential , Female , Humans , Male , Phobic Disorders/epidemiology , Phobic Disorders/psychology , Severity of Illness Index , Social Behavior , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...